News: Neuro-Hitech Expands Size of Clinical Trial for Use of Huperzine A in the Treatment of Alzheimer's Disease. Genetic Engineering News - Biotechno

News: Neuro-Hitech Expands Size of Clinical Trial for Use of Huperzine A in the Treatment of Alzheimer's Disease. Genetic Engineering News - Biotechnology from Bench to Business: "Neuro-Hitech, Inc. (OTCBB: NHPI), a biopharmaceutical company focused on the development and commercialization of next-generation compounds against proven targets for neurodegenerative diseases, today announced that it has decided to expand the enrollment level for its Phase II clinical trial on the efficacy of Huperzine A, a highly promising second-generation acetylcholinesterase inhibitor, for people with mild to moderate Alzheimer's. The trial will be expanded by 30 to 60 participants,"